KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Resmed (RMD) Gross Profit (2016 - 2025)

Resmed (RMD) has disclosed Gross Profit for 17 consecutive years, with $878.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gross Profit rose 16.96% year-over-year to $878.7 million, compared with a TTM value of $3.3 billion through Dec 2025, up 14.22%, and an annual FY2025 reading of $3.1 billion, up 15.05% over the prior year.
  • Gross Profit was $878.7 million for Q4 2025 at Resmed, up from $820.8 million in the prior quarter.
  • Across five years, Gross Profit topped out at $878.7 million in Q4 2025 and bottomed at $447.3 million in Q1 2021.
  • Average Gross Profit over 5 years is $636.4 million, with a median of $617.6 million recorded in 2023.
  • The sharpest move saw Gross Profit fell 0.53% in 2021, then grew 25.76% in 2023.
  • Year by year, Gross Profit stood at $504.3 million in 2021, then increased by 14.95% to $579.7 million in 2022, then grew by 11.6% to $646.9 million in 2023, then rose by 16.13% to $751.3 million in 2024, then rose by 16.96% to $878.7 million in 2025.
  • Business Quant data shows Gross Profit for RMD at $878.7 million in Q4 2025, $820.8 million in Q3 2025, and $820.1 million in Q2 2025.